Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum) header
Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum) profile picture

An educational platform dedicated to educating clinicians around the globe on the science of immune-mediated inflammatory diseases.

Glasgow, UK
Joined August 2013
Photo by Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum)Photo by Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum)Photo by Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum)Photo by Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum)Photo by Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum)Photo by Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum)Photo by Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum)Photo by Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum)Photo by Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum)Photo by Immune-Mediated Inflammatory Disease Forum (@TheIMIDForum)
Deodhar et al. evaluated the long-term efficacy of bimekizumab in patients with PsA across the GRAPPA domains, PsA-related conditions, and comorbidities. imidforum.com/publications/9…
24
Russell et al. found that b/tsDMARD monotherapy increased the likelihood of DAS28 remission at 6 months compared with MTX in MTX-naïve patients with early RA. imidforum.com/publications/9…
28
NEW PsA publication available now! 📑 Dive into the latest research on #PsA with our new in-depth slide decks and literature highlights! Available now for free on the #IMIDForum: imidforum.com/publications/9…
48
NEW axSpA publication 📑 Maksymowych et al. evaluated the impact of 2-year treatment with bimekizumab on spinal MRI inflammatory and structural lesions in patients with r-axSpA. Dive into the full findings now: imidforum.com/publications/9…
46
Don't forget - November's #PsA author interview is available on the #IMIDForum! 🎬 Stay up to date with the newest research and clinical insights. Access them for free today: imidforum.com/podcasts/episo…
36
BRAND NEW axSpA and PsA resources coming tomorrow on the IMID Forum! 📑🎉 Keep your eyes peeled 👀
31
In this real-world cohort of older adults with RA, Ibis et al. showed that initiation of JAK inhibitors was not associated with higher risks of MACE, VTE, malignancy, or mortality compared with TNFi(s). imidforum.com/publications/9…
54
Don’t miss out on the latest #PsA author interview 🎬 on the #IMIDForum, hosted by Professor Peter Nash and Doctor André Lucas Ribeiro ➡️ imidforum.com/podcasts/episo…
61
Dive into the latest research on #RA with our new in-depth slide decks and literature highlights! Available now for free on the #IMIDForum: imidforum.com/literature-rev…
41
This month on our author interview, Professor Peter Nash and Doctor André Lucas Ribeiro describe the patient profiles, treatment patterns, clinical outcomes, and safety of intentional dual b/tsDMARD therapy in PsA. Catch this insightful discussion on the #IMIDForum: imidforum.com/podcasts/episo…
50
👉 Our November literature search identified 7 new papers in #AxSpA! 👀 View the results by clicking the link below: imidforum.com/resources
51
👉 Our November literature search identified 15 new papers in #PsA! 👀 View the results by clicking the link below: imidforum.com/resources
32
Stay informed with our latest #RA literature highlights and detailed slide decks. Now available for free on the #IMIDForum: imidforum.com/publications
34
Check out our newest #PsA author interview 🎬 featuring Professor Peter Nash and Doctor André Lucas Ribeiro over on the #IMIDForum website: imidforum.com/podcasts/episo…
46
Ibis et al. reported that among adults aged ≥75 years with RA, JAK inhibitor initiation was not associated with significantly higher risks of MACE, VTE, malignancy or mortality compared with TNFi(s) over 3 years. imidforum.com/publications/9… #IMIDForum
39
Russell et al. reported higher remission rates with initial b/tsDMARDs plus MTX than with MTX alone, with benefits evident from 3 months. imidforum.com/publications/9… #IMIDForum
42
What about cell-directed therapies as a completely new way of treating axial spondyloarthritis in future? Let's hear from Professor Atul Deodhar regarding a new discovery at #ACR2026! Leave a comment below to share your thoughts or questions about this innovative approach ⬇️⬇️
1
1
1
126
🌟 Highlighted 🌟 9:45am-10:00am 2942: Ixekizumab Plus Tirzepatide Demonstrated Greater Disease Control at 52 Weeks Versus Ixekizumab Alone With Incremental Improvement From Week 36 in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomised Clinical Trial Joseph Merola, MD, MSc, FACR, FAAD #ACR2026
1
61
Merola et al. reported that IXE+TZP showed benefit in disease activity as early as Week 4. Results from TOGETHER-PsA provide longer-term data supporting the concomitant use of IXE and TZP to manage PsA as an immunometabolic disease, with potential to improve disease control, QoL, cardiometabolic outcomes, and overall health #PsA
57
🌟 Highlighted 🌟 8:30am-8:45am LB21: TARA: A Phase 3 Head-to-Head Trial of Girocitinib vs Tofacitinib in Patients with Active Rheumatoid Arthritis Refractory to bDMARDs Xiaofeng Zeng, MD #ACR2026
1
96
Girocitinib achieved a higher ACR50 response at Week 24 compared with tofacitinib in patients with inadequate response or intolerance to 21 bDMARD. Data from long-term follow-up will characterise uncommon and longer-term safety outcomes
27